Yan Leyfman, Co-founder and executive director of MedNews Week, shared an article by Katsiaryna Marhelava, et al. on LinkedIn:
“CD19 CAR-T cells have revolutionized treatment for relapsed/refractory B-cell malignancies—but up to 50% of patients relapse, often due to CD19 antigen loss or lineage switching.
In search of a new target, researchers identified LILRB1 (CD85j) via cell surface proteomics from high-risk B-ALL patient samples.
Why LILRB1?
- Expressed on monocytes & B-cells.
- Stably present in B-ALL & B-NHL—even after CD19/CD20-based therapies.
- Notably expressed in monocytic AML too.
LILRB1 CAR-T cells showed: Antigen-specific killing of B-ALL/B-NHL cells (even CD19-resistant ones).
- In vivo efficacy in B-ALL xenograft models.
- Cytotoxicity against AML cells in vitro & in vivo.
These findings position LILRB1 CAR-T as a promising next-gen therapy for blood cancers, including those resistant to current immunotherapies.
Time to rethink the frontline in CAR-T innovation.”
LILRB1-directed CAR-T cells for the treatment of hematological malignancies.
Authors: Katsiaryna Marhelava, et al.
